SAKAR Sakar Healthcare Q2 FY26 results (Jul–Sep 2025) and concall
Sakar Healthcare reported strong H1 FY26 results with revenue growing 31.4% YoY to ₹110.30 crores, driven by a significant increase in oncology segment contribution. While Q2 EBITDA margins saw a temporary dip to 20% due to one-time expenses, management reaffirmed its FY26 revenue target of ₹280 crores and expects margins to recover. The company is progressing with European marketing authorizations and aims for substantial growth in oncology exports.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 43 | 50 | 53 | 58 |
| EBITDA | 12 | 16 | 13 | 11 |
| Net profit | 5 | 6 | 5 | 5 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
